Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Xospata (gilteritinib) for Acute Myeloid Leukaemia with FLT3 Mutation

Xospata® (gilteritinib) is a tyrosine kinase inhibitor indicated for the treatment of acute myeloid leukaemia in adult patients with FLT3 mutation. Image courtesy of Astellas Pharma.



  • Xospata
  • Xospata
  • Xospata
  • Xospata
Close
Close
Close

Go Top